Table 1. Immunological features of a patient with CVID.
| Patient | Reference ranges | |
|---|---|---|
| Lymphocyte subsets (%) | ||
| CD3+ | 744 (62%) | 844–2395 (65–80%) |
| CD3+CD4+ | 504 (42%) | 437–1597 (31–56%) |
| CD3+CD8+ | 204 (17%) | 281–1125 (17–34%) |
| CD4+/CD8+ ratio | 2.57 | 0.78–2.21 |
| CD19+ | 60 (5%) | 132–399 (4–16%) |
| CD3-CD56+CD16+ | 36 (3%) | 120–424 (4–16%) |
| Lymphocyte proliferation to antigens and mitogens (c.p.m.) | ||
| Mumps | 42 | 2052–26 495 |
| Tetanus toxoid | 762 | 6092–94 539 |
| Candida albicans | 279 | 13 249–60 917 |
| PPD | 174 | 548–2580 |
| PHA | 83 013 | 114 881–289 206 |
| Con A | 97 975 | 131 199–252 925 |
| PWM | 15 320 | 20 171–78 728 |
| Serum immunoglobulins (mg dl−1) | ||
| IgG | 516 | 694–1618 |
| IgA | 44 | 68–378 |
| IgM | 95 | 65–263 |
| IgE (IU l−1) | 110 | 10–150 |
| Specific antibodies | ||
| Streptococcus pneumoniae (μg ml−1, 14 serotypes) | 0.0–0.3a | >1.3b |
| Complement | ||
| CH50 (U ml−1) | 267 | (101–300) |
| C3 (mg dl−1) | 113 | (88–201) |
| C4 (mg dl−1) | 31 | (16–47) |
| Oxidative respiratory burst (MFI) | ||
| Unactivated | 54 | 70 |
| PMA-activated | 404 | 873 |
| Ratio of activated/unactivated | 7.5 | 12.5 |
Abbreviations: ConA, concanavalin A; CVID, common variable immunodeficiency; Ig, immunoglobulin; MFI, mean fluorescence intensity; PHA, phytohemagglutinin; PMA, phorbol myristate acetate; PPD, purified protein derivative; PWM, pokeweed mitogen.
a
After Pneumovax-23 response. Patient did not respond to any of the 14 serotypes.
b
1.3 protective titers. × 4 fold increase following Pneumovax-23 against at least 70% serotypes.